By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Growth in its Life Sciences and Diagnostics segment helped Danaher's second-quarter sales expand 15 percent year over year, the company reported today.

Overall, sales increased to $3.71 billion for the three months ended July 1, compared to $3.22 billion a year ago, helped along by a 31 percent increase in its Life Sciences and Diagnostics business, which spiked to $704.8 million from $540.1 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.